mTOR Inhibitors (Temsirolimus and Everolimus)

Temsirolimus (Torisel) and everolimus (Afinitor) are mTOR inhibitorswhich were launched at almost the same time. The mTOR inhibitors were admitted first as anticancer drugs for renal cell cancer, and then, the indications with everolimus were expanded to cases of radically unresectable or metastatic neuroendocrine tumors, breast cancer, and nodular sclerosis.